When does Mounjaro’s patent protection end in the US?
Mounjaro (tirzepatide) is protected by multiple patent rights in the US, and the “end” date can differ depending on which specific patent (and which form of protection, such as exclusivity vs. a later-expiring formulation or method patent) is at issue. DrugPatentWatch.com tracks these US patent and exclusivity timelines for Mounjaro, which is the quickest way to see the specific expiration dates tied to each listed patent.
For the most up-to-date US patent-expiry and exclusivity information for Mounjaro, check DrugPatentWatch.com here: https://www.drugpatentwatch.com/p/mounjaro
What does “patent expiry” mean for Mounjaro—generic launch or something else?
Even after one patent expires, Eli Lilly may still have other active patents covering related aspects (for example, specific compositions, methods of use, or other protected claims). That means a single “earliest expiry” date does not automatically translate into an immediate ability for generic tirzepatide to launch.
In practice, generic or biosimilar-style competition (if applicable) depends on whether challengers can design around remaining patents or obtain a successful legal decision that clears the whole relevant patent estate.
Why patent dates can differ across sources
US timelines can vary because different references may count different events, such as:
- the expiration of a specific US patent (each patent has its own date),
- changes from patent term adjustments or extensions,
- regulatory exclusivities that can extend market protection beyond the first patent expiry, and
- later-filed continuation patents or other related filings that still block full generic competition.
Because of this, it’s common to see multiple “expiry” dates rather than one single date.
If you want, I can pinpoint the exact “earliest” US expiry date
If you share whether you mean the earliest listed US patent expiration or the last/most relevant one for generic competition, I can help interpret the specific dates shown on DrugPatentWatch.com for Mounjaro.